Cliff Asness's EW Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 2.24 M shares of Edwards Lifesciences Corporation (EW) worth $191.11 M, representing 0.10% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in EW, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 4.23 M shares. Largest reduction occurred in Q1 2016, reducing 3.64 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Edwards Lifesciences Corporation (EW) Holding Value Over Time
Track share changes against reported price movement
Quarterly Edwards Lifesciences Corporation (EW) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +160,405 | Add 7.71% | 2.24 M | $85.25 |
| Q3 2025 | +1.11 M | Add 114.53% | 2.08 M | $77.38 |
| Q2 2025 | +51,670 | Add 5.63% | 970,207 | $78.21 |
| Q1 2025 | +709,648 | Add 339.72% | 918,537 | $71.18 |
| Q4 2024 | +63,313 | Add 43.49% | 208,889 | $74.03 |
| Q3 2024 | -163,543 | Reduce 52.91% | 145,576 | $65.99 |
| Q2 2024 | -33,755 | Reduce 9.84% | 309,119 | $92.37 |
| Q1 2024 | -70,714 | Reduce 17.10% | 342,874 | $95.22 |
| Q4 2023 | +144,166 | Add 53.51% | 413,588 | $76.25 |
| Q3 2023 | -209,826 | Reduce 43.78% | 269,422 | $69.28 |
| Q2 2023 | -91,339 | Reduce 16.01% | 479,248 | $93.69 |
| Q1 2023 | +82,192 | Add 16.83% | 570,587 | $81.47 |
| Q4 2022 | -38,616 | Reduce 7.33% | 488,395 | $74.08 |
| Q3 2022 | +71,289 | Add 15.64% | 527,011 | $82.63 |
| Q2 2022 | -20,318 | Reduce 4.27% | 455,722 | $94.60 |
| Q1 2022 | -148,559 | Reduce 23.78% | 476,040 | $117.72 |
| Q4 2021 | +2,754 | Add 0.44% | 624,599 | $129.55 |
| Q3 2021 | -69,469 | Reduce 10.05% | 621,845 | $113.21 |
| Q2 2021 | -187,193 | Reduce 21.31% | 691,314 | $103.57 |
| Q1 2021 | -160,631 | Reduce 15.46% | 878,507 | $83.45 |
| Q4 2020 | -422,552 | Reduce 28.91% | 1.04 M | $89.61 |
| Q3 2020 | -749,599 | Reduce 33.90% | 1.46 M | $79.09 |
| Q2 2020 | -108,950 | Reduce 4.70% | 2.21 M | $67.57 |
| Q1 2020 | +200,142 | Add 9.44% | 2.32 M | $62.87 |
| Q4 2019 | -232,596 | Reduce 9.89% | 2.12 M | $77.50 |
| Q3 2019 | -572,769 | Reduce 19.58% | 2.35 M | $72.90 |
| Q2 2019 | +204,942 | Add 7.53% | 2.93 M | $61.58 |
| Q1 2019 | +261,654 | Add 10.64% | 2.72 M | $63.28 |
| Q4 2018 | +1.43 M | Add 137.96% | 2.46 M | $51.06 |
| Q3 2018 | +398,754 | Add 62.84% | 1.03 M | $58.03 |
| Q2 2018 | +226,320 | Add 55.44% | 634,578 | $48.52 |
| Q1 2018 | +65,460 | Add 19.10% | 408,258 | $46.51 |
| Q4 2017 | -50,085 | Reduce 12.75% | 342,798 | $37.57 |
| Q3 2017 | -157,161 | Reduce 28.57% | 392,883 | $36.44 |
| Q2 2017 | -512,625 | Reduce 48.24% | 550,044 | $39.41 |
| Q1 2017 | -704,046 | Reduce 39.85% | 1.06 M | $31.36 |
| Q4 2016 | -1.82 M | Reduce 50.80% | 1.77 M | $31.23 |
| Q3 2016 | -514,458 | Reduce 12.53% | 3.59 M | $40.19 |
| Q2 2016 | -1.6 M | Reduce 28.02% | 4.1 M | $33.24 |
| Q1 2016 | -3.64 M | Reduce 38.96% | 5.7 M | $29.40 |
| Q4 2015 | -3.3 M | Reduce 26.09% | 9.34 M | $26.33 |
| Q3 2015 | -1.77 M | Reduce 12.31% | 12.64 M | $23.69 |
| Q2 2015 | +2.81 M | Add 24.20% | 14.41 M | $23.74 |
| Q1 2015 | +3.32 M | Add 40.05% | 11.61 M | $23.74 |
| Q4 2014 | +4.23 M | Add 104.34% | 8.29 M | $21.23 |
| Q3 2014 | +3.73 M | Add 1138.72% | 4.06 M | $17.02 |
| Q2 2014 | +264,000 | Add 416.31% | 327,414 | $14.31 |
| Q1 2014 | -316,800 | Reduce 83.32% | 63,414 | $12.36 |
| Q4 2013 | +60,300 | Add 18.85% | 380,214 | $10.96 |
| Q3 2013 | -271,860 | Reduce 45.94% | 319,914 | $11.61 |
| Q2 2013 | +591,774 | Add 0.00% | 591,774 | $11.20 |
| Q4 2012 | +208,812 | Add 0.00% | 208,812 | $15.03 |
Cliff Asness's Edwards Lifesciences Corporation Investment FAQs
Cliff Asness first purchased Edwards Lifesciences Corporation (EW) in Q4 2012, acquiring 208,812 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Edwards Lifesciences Corporation (EW) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Edwards Lifesciences Corporation (EW) was in Q4 2014, adding 8,287,470 shares worth $175.94 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 2,241,751 shares of Edwards Lifesciences Corporation (EW), valued at approximately $191.11 M.
As of the Q4 2025 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.10% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Edwards Lifesciences Corporation (EW) was 14,414,910 shares, as reported at the end of Q2 2015.